Findings from the NordiCC (Nordic Colorectal Cancer) group, a 13-year follow-up study that "enrolled men and women aged 55-64 years, who were randomly allocated to colonoscopy screening or no screening" was recently published in The Lancet. Study authors commented that they did not observe a clinically relevant cancer stage shift between the screening and non-screened groups of participants. Further, "stage shift of cancer due to screening applies only to cancers detected at screening or surveillance after screening." At 13 year follow-up, screening-detected colorectal cancer only occurred in 16% in the screening group; "cancers detected later were due to clinical symptoms, as there was no colonoscopy screening."
Click here to read more about the NordiCC study.
Sources mentioned:
- Kaminski M, Kalager M, Løberg, et al. for the NordiCC Study Group. Long-term effects of colonoscopy screening on colorectal cancer incidence and mortality: a multicountry, population-based randomised controlled trial . The Lancet; Published online 4 May 2026. DOI: 10.1016/S0140-6736(26)00508-8
- Shaukat A. Colonoscopy, cancer prevention, and the new arithmetic of benefit . The Lancet; Published online 4 May 2026. DOI: 10.1016/S0140-6736(26)00794-4
No comments:
Post a Comment